Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy. (2022). Farmeconomia. Health Economics and Therapeutic Pathways, 23(1). https://doi.org/10.7175/fe.v23i1.1539